MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from sales and
maturities of marketable...
$89,041K
Net cash provided by
(used in) investing...
$48,365K
Canceled cashflow
$40,676K
Net decrease in cash
and cash...
-$4,610K
Canceled cashflow
$48,365K
Stock-based compensation
expense
$12,384K
Accounts payable
$8,447K
Accounts receivable,
prepaid expenses and...
-$6,138K
Revaluation of contingent
consideration
$2,300K
Depreciation and
amortization
$454K
Purchases of marketable
securities
$39,732K
Payments of deferred
transaction consideration...
$833K
Purchases of property and
equipment
$111K
Net cash used in
operating activities
-$47,113K
Canceled cashflow
$29,723K
Net cash (used in)
provided by financing...
-$5,862K
Net loss
-$64,923K
Accrued expenses and
other liabilities
-$8,097K
Deferred income
-$3,816K
Payments of deferred
transaction consideration...
$5,416K
Payments of employee
withholding taxes related to...
$446K
Back
Back
Cash Flow
source: myfinsight.com
Aclaris Therapeutics, Inc. (ACRS)
Aclaris Therapeutics, Inc. (ACRS)